Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.
$100M sweet spot round size
2017
$100M
from 2 investors over 1 rounds
HotSpot Therapeutics, Inc. raised $100M on December 29, 2021
Investors: Pivotal bioVenture Partners and + 8 Other investors